1
|
Pyrido[2,3- d]pyrimidin-7(8 H)-ones: Synthesis and Biomedical Applications. Molecules 2019; 24:molecules24224161. [PMID: 31744155 PMCID: PMC6891647 DOI: 10.3390/molecules24224161] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Revised: 11/11/2019] [Accepted: 11/13/2019] [Indexed: 12/20/2022] Open
Abstract
Pyrido[2,3-d]pyrimidines (1) are a type of privileged heterocyclic scaffolds capable of providing ligands for several receptors in the body. Among such structures, our group and others have been particularly interested in pyrido[2,3-d]pyrimidine-7(8H)-ones (2) due to the similitude with nitrogen bases present in DNA and RNA. Currently there are more than 20,000 structures 2 described which correspond to around 2900 references (half of them being patents). Furthermore, the number of references containing compounds of general structure 2 have increased almost exponentially in the last 10 years. The present review covers the synthetic methods used for the synthesis of pyrido[2,3-d]pyrimidine-7(8H)-ones (2), both starting from a preformed pyrimidine ring or a pyridine ring, and the biomedical applications of such compounds.
Collapse
|
3
|
Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, Hudry C, Miceli-Richard C, Molto A, Pham T, Saraux A, Dougados M. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine 2018; 85:275-284. [PMID: 29407043 DOI: 10.1016/j.jbspin.2018.01.006] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/29/2017] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To update French Society for Rheumatology recommendations about the management in clinical practice of patients with spondyloarthritis (SpA). SpA is considered across the range of clinical phenotypes (axial, peripheral, and entheseal) and concomitant manifestations. Psoriatic arthritis is included among the SpA phenotypes. METHODS According to the standard procedure advocated by the EULAR for developing recommendations, we first reviewed the literature published since the previous version of the recommendations issued in June 2013. A task force used the results to develop practice guidelines, which were then revised and graded using AGREE II. RESULTS Four general principles and 15 recommendations were developed. The first four recommendations deal with treatment goals and general considerations (assessment tools and comorbidities). Recommendations 5 and 6 are on non-pharmacological treatments. Recommendation 7 is about nonsteroidal anti-inflammatory drugs, which are the cornerstone of the treatment, and recommendations 8 to 10 are on analgesics, glucocorticoid therapy, and conventional disease-modifying antirheumatic drugs. Biologics are the focus of recommendations 11 through 14, which deal with newly introduced drug classes, including their indications (active disease despite conventional therapy and, for nonradiographic axial SpA, objective evidence of inflammation) and monitoring, and with patient management in the event of treatment failure or disease remission. Finally, recommendation 15 is about surgical treatments. CONCLUSION This update incorporates recent data into a smaller number of more simply formulated recommendations, with the goal of facilitating their use for guiding the management of patients with SpA.
Collapse
Affiliation(s)
- Daniel Wendling
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France; EA4266, université Bourgogne Franche-Comté, place Goudimel, 25030 Besançon, France.
| | - Cédric Lukas
- EA2415, département de rhumatologie, institut universitaire de recherche clinique, université de Montpellier, CHU de Lapeyronie, 34000 Montpellier, France
| | - Clément Prati
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France; EA4267, FHU Increase, université Bourgogne Franche-Comté, 25030 Besançon, France
| | - Pascal Claudepierre
- Service de rhumatologie, groupe hospitalier Henri-Mondor, AP-HP, Créteil, 94000, France; EA 7379-épiderme, université Paris Est Créteil, Créteil, 94000, France
| | - Laure Gossec
- UPMC universié Paris 06, Sorbonne universités, institut Pierre-Louis d'épidémiologie et de santé publique (UMRS 1136), 75252 Paris, France; Rheumatology department, hôpital Pitié Salpêtrière, AP-HP, 75013 Paris, France
| | - Philippe Goupille
- Service de rhumatologie, CHRU de Tours, 37000 Tours, France; UMR CNRS 7292, université François-Rabelais, 37000 Tours, France
| | - Christophe Hudry
- Cabinet de rhumatologie, 75008 Paris, France; Paris Descartes university, department of rheumatology, hôpital Cochin, AP-HP, EULAR center of excellence, 75014 Paris, France
| | - Corinne Miceli-Richard
- Paris Descartes university, department of rheumatology, hôpital Cochin, AP-HP, EULAR center of excellence, 75014 Paris, France
| | - Anna Molto
- Paris Descartes university, department of rheumatology, hôpital Cochin, AP-HP, EULAR center of excellence, 75014 Paris, France; INSERM (UU1153), clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, 75014 Paris 14, France
| | - Thao Pham
- Service de rhumatologie, hôpital Sainte-Marguerite, Aix-Marseille université, AP-HM, 13000 Marseille, France
| | - Alain Saraux
- Service de rhumatologie, CHU de Brest, 29609 Brest cedex, France; UMR1227, université de Bretagne Occidentale, labex IGO, Brest, 29000 France
| | - Maxime Dougados
- Paris Descartes university, department of rheumatology, hôpital Cochin, AP-HP, EULAR center of excellence, 75014 Paris, France; INSERM (UU1153), clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, 75014 Paris 14, France
| |
Collapse
|